Aleix Prat, Director of the Cancer Institute at the Hospital Clinic of Barcelona, shared a post on LinkedIn:
“Thrilled to share our latest publication in ESMO Open!
In our study, we explored the utility of the HER2DX genomic assay in predicting pathologic complete response (pCR) in patients with HER2+ stage III inflammatory breast cancer (IBC), a rare and aggressive HER2+ disease.
Key Highlights
IBC vs. non-IBC: IBC is associated with worse clinical outcomes compared to non-IBC, but HER2DX pCR scores were significant predictors of pCR in both groups.
Predictive power: In 5 patient cohorts, HER2DX pCR scores stratified patients into high, medium, and low groups, with pCR rates of 68.9%, 58.5%, and 16.3%, respectively.
Potential for de-escalation: Elevated pCR rates in HER2-positive IBC with high HER2DX pCR scores suggest that treatment de-escalation may be feasible in selected patients.
A heartfelt thank you to our collaborators and all who contributed to this work. Together, we continue to push the boundaries of precision oncology.
Read the full article.”
Authors: F. Lynce, O. Martínez-Sáez, B. Walbaum, F. Brasó-Maristany, A.G. Waks, P. Villagrasa, G. Villacampa Javierre, E. Sanfeliu, P. Galván, L. Paré, L.M. Anderson, C.M. Perou, J.S. Parker, A. Vivancos, M.K. DiLullo, S. Pernas, E.P. Winer, B. Overmoyer, E.A. Mittendorf, C. Bueno-Muiño, M. Martín, A. Prat, S.M. Tolaney
